Literature DB >> 6460092

Subacute myelo-optic neuropathy (SMON). First neuro-pathological report outside Japan.

J R Ricoy, A Ortega, A Cabello.   

Abstract

A 72-year-old Caucasian woman developed degeneration of the spinal cord long tracts, polyneuropathy, and optic atrophy after chronic ingestion of clioquinol (200 mg/day) since she was 45. Diseases with a similar clinical picture, notably vitamin B12 deficiency (B12D), and subacute myelo-optic neuropathy (SMON), are discussed with regard to the pathologic findings. In our patient findings were different from those reported in B12D, but similar to those in SMON. If, as we believe, our patient was suffering from the same disease as the SMON described by Japanese authors, this is the first case reported outside Japan in which pathological verification has been obtained.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6460092     DOI: 10.1016/0022-510x(82)90010-7

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  3 in total

1.  Supramolecular synthon pattern in solid clioquinol and cloxiquine (APIs of antibacterial, antifungal, antiaging and antituberculosis drugs) studied by ³⁵Cl NQR, ¹H-¹⁷O and ¹H-¹⁴N NQDR and DFT/QTAIM.

Authors:  Jolanta Natalia Latosińska; Magdalena Latosińska; Marzena Agnieszka Tomczak; Janez Seliger; Veselko Zagar
Journal:  J Mol Model       Date:  2010-11-16       Impact factor: 1.810

2.  Idiosyncratic quinoline central nervous system toxicity: Historical insights into the chronic neurological sequelae of mefloquine.

Authors:  Remington L Nevin
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2014-04-05       Impact factor: 4.077

3.  Founder genetic variants of ABCC4 and ABCC11 in the Japanese population are not associated with the development of subacute myelo-optico-neuropathy (SMON).

Authors:  Hideki Matsumoto; Hideo Sasai; Norio Kawamoto; Masato Katsuyama; Makoto Minamiyama; Satoshi Kuru; Toshiyuki Fukao; Hidenori Ohnishi
Journal:  Mol Genet Genomic Med       Date:  2021-12-24       Impact factor: 2.473

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.